TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33402584

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) boost (21 Gy in three fractions) combined with whole pelvic radiotherapy (RT) (50 Gy in 25 fractions)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) boost
Number of subjects: 34
Study: 35078490

Group type: EXPERIMENTAL
Intervention: MR-guided SBRT of the primary pancreatic cancer (pPCa) with 5 × 6.6 Gy at 80% isodose with continuation of SoC-CT thereafter
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard of care chemotherapy (SoC-CT) without SBRT
Number of subjects: 92
Study: 33327737

Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg twice/day
Number of subjects: 794

Group type: COMPARATOR
Intervention: Clopidogrel monotherapy
Number of subjects: 794
Study: 35723920

Group type: EXPERIMENTAL
Intervention: Pneumatic vitreolysis
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pars plana vitrectomy
Number of subjects: 30
Study: 32914197

Group type: EXPERIMENTAL
Intervention: Corticomedullary phase CT
Number of subjects: 177

Group type: COMPARATOR
Intervention: Nephrographic phase CT
Number of subjects: 177

Group type: COMPARATOR
Intervention: Non-contrast-enhanced CT
Number of subjects: 177
Study: 33952741

Group type: EXPERIMENTAL
Intervention: Grains of Paradise (GP) extract (40 mg/d)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 32212979

Group type: EXPERIMENTAL
Intervention: Continuous monitoring of vital signs with SensiumVitals in addition to intermittent monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittent vital signs monitoring alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SensiumVitals in addition to intermittent monitoring
Number of subjects: 0
Study: 36164099

Group type: EXPERIMENTAL
Intervention: Lenalidomide 20mg PO d1-21 of a 28-d cycle + rituximab IV 375mg/m2/week for 12 cycles (R2)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Rituximab maintenance for 18 months
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Induction phase (R2)
Number of subjects: 394
Study: 32541510

Group type: EXPERIMENTAL
Intervention: Yuanhu Zhitong dropping pills
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diclofenac sodium sustained-release capsule
Number of subjects: 60
Study: 34986007

Group type: EXPERIMENTAL
Intervention: Robot-Assisted Radical Cystectomy (RARC) with intracorporeal urinary diversion
Number of subjects: 116

Group type: COMPARATOR
Intervention: Open Radical Cystectomy (ORC)
Number of subjects: 116
Study: 33970295

Group type: EXPERIMENTAL
Intervention: Anatomic double-bundle ACL reconstruction (DB ACLR)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Anatomic single-bundle ACL reconstruction (SB ACLR)
Number of subjects: 57
Study: 32857151

Group type: EXPERIMENTAL
Intervention: Short-term integrated palliative care (SIPC)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: SIPC
Number of subjects: 350
Study: 616081112

Group type: EXPERIMENTAL
Intervention: Topical ketorolac 5mg/ml
Number of subjects: 20

Group type: COMPARATOR
Intervention: Topical bromfenac 9mg/ml
Number of subjects: 20
Study: 34610775

Group type: EXPERIMENTAL
Intervention: Rational emotive occupational intervention (REBOI) for 12 weeks
Number of subjects: 168

Group type: COMPARATOR
Intervention: Conventional means of counseling (waitlisted control group)
Number of subjects: 168
Study: 33836778

Group type: EXPERIMENTAL
Intervention: Interceptor G2 (IG2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorfenapyr treated net
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both insecticide components of IG2
Number of subjects: 0

Group type: COMPARATOR
Intervention: WHO susceptibility tests with pyrethroid papers
Number of subjects: 0
Study: 32451827

Group type: EXPERIMENTAL
Intervention: Oral paracetamol (15 mg/kg/dose)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral ibuprofen (10 mg/kg/dose)
Number of subjects: 50
Study: 34216423

Group type: EXPERIMENTAL
Intervention: Therapeutic clowning
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 166
Study: 32057000

Group type: EXPERIMENTAL
Intervention: Betamethasone acetate 0.1%
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 62
Study: 32820548

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rifampicin
Number of subjects: 0
Study: 34360051

Group type: EXPERIMENTAL
Intervention: Bayesian estimators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frequentist estimators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjustment for prognostic baseline covariates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regression model
Number of subjects: 0
Study: 32164118

Group type: EXPERIMENTAL
Intervention: Facial nerve monitoring during acoustic schwannoma resection
Number of subjects: 80
Study: 36102776

Group type: EXPERIMENTAL
Intervention: Integrated oncogeriatric care
Number of subjects: 154

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 154
Study: 33622882

Group type: EXPERIMENTAL
Intervention: Minicholecystectomy (MC)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 88
Study: 35758374

Group type: EXPERIMENTAL
Intervention: High-dose Resveratrol (500 mg/d)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Middle-dose Resveratrol (250 mg/d)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Low-dose Resveratrol (125 mg/d)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 33883102

Group type: EXPERIMENTAL
Intervention: Meals served in kindergartens (10-day menus)
Number of subjects: 1746
Study: 32207636

Group type: EXPERIMENTAL
Intervention: In-office ICM insertion
Number of subjects: 482

Group type: COMPARATOR
Intervention: In-hospital ICM insertion
Number of subjects: 482
Study: 34264701

Group type: EXPERIMENTAL
Intervention: TranS‐C + UC (n = 61; 8 individual weekly sessions)
Number of subjects: 121
Study: 35484442

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33066746

Group type: EXPERIMENTAL
Intervention: CONNACT Model of Care (MoC) for 3 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CONNACT MoC
Number of subjects: 100
Study: 32419414

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketofol
Number of subjects: 0
Study: 34974435

Group type: EXPERIMENTAL
Intervention: Neurofeedback treatment reinforcing reductions in theta activity
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group receiving random rewards
Number of subjects: 20
Study: 32343348

Group type: EXPERIMENTAL
Intervention: Lemborexant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zolpidem Tartrate Extended Release
Number of subjects: 0
Study: 35737076

Group type: EXPERIMENTAL
Intervention: Robot-Assisted Therapy (RT)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Mirror Therapy (MT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Active Control Treatment (AC)
Number of subjects: 37
Study: 34190086

Group type: EXPERIMENTAL
Intervention: E-Fit group (high-intensity interval exercises, 6-month home-based digitally supported program)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: E-Fit group
Number of subjects: 40
Study: 32949103

Group type: EXPERIMENTAL
Intervention: Early Access to ART for All (EAAA)
Number of subjects: 3405

Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 3405
Study: 36543445

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) for focal CAD
Number of subjects: 103

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI) for diffuse CAD
Number of subjects: 103
Study: 32250021

Group type: EXPERIMENTAL
Intervention: Daprodustat 2-mg tablet
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Daprodustat 4-mg tablet
Number of subjects: 64
Study: 36342737

Group type: EXPERIMENTAL
Intervention: Nitrous oxide system during MFU-V treatment
Number of subjects: 10
Study: 32058976

Group type: EXPERIMENTAL
Intervention: Full-featured study app
Number of subjects: 328

Group type: COMPARATOR
Intervention: Control group with fewer app features
Number of subjects: 328
Study: 33413982

Group type: EXPERIMENTAL
Intervention: SOVTE-Therapeutic Program (SOVTE-TP)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Vocal Function Exercises (VFE)
Number of subjects: 18
Study: 33135429

Group type: EXPERIMENTAL
Intervention: Lacidipine (4–6 mg/day)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Amlodipine (5–7.5 mg/day)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 269

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 269
Study: 32943093

Group type: EXPERIMENTAL
Intervention: Salford Lung Studies (SLS)
Number of subjects: 10
Study: 35121270

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for antenatal depression
Number of subjects: 444

Group type: COMPARATOR
Intervention: Control group (not intervened)
Number of subjects: 444
Study: 33298407

Group type: EXPERIMENTAL
Intervention: First facemask application
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Subsequent facemask applications
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Facemask applications associated with apnoea
Number of subjects: 128
Study: 33006068

Group type: EXPERIMENTAL
Intervention: Unsupervised web‐based testing
Number of subjects: 17473

Group type: COMPARATOR
Intervention: Supervised paper‐based testing
Number of subjects: 17473

Group type: COMPARATOR
Intervention: Supervised computerized testing
Number of subjects: 17473
Study: 32145830

Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg twice daily
Number of subjects: 663

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 663
Study: 33550450

Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 153
Study: 34716989

Group type: EXPERIMENTAL
Intervention: Nonviolent communication (NVC) training for 2.5 days
Number of subjects: 312

Group type: COMPARATOR
Intervention: Control group (no NVC training)
Number of subjects: 312
Study: 35688587

Group type: EXPERIMENTAL
Intervention: Propofol titrated by anaesthesia practitioners able to interpret EEG
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard monitoring (BIS)
Number of subjects: 200
Study: 33760371

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC)
Number of subjects: 11
Study: 33161581

Group type: EXPERIMENTAL
Intervention: Screencast training videos
Number of subjects: 53

Group type: COMPARATOR
Intervention: Traditional training videos on CBCT and implant planning
Number of subjects: 53
Study: 35500028

Group type: COMPARATOR
Intervention: Prenatal multiple micronutrient supplementation (MMS)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Prenatal lipid‐based nutrient supplementation (LNS)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Routine iron‐folic acid (IFA) supplementation
Number of subjects: 53
Study: 32301640

Group type: EXPERIMENTAL
Intervention: Transfer Sheet (TS)
Number of subjects: 72

Group type: COMPARATOR
Intervention: S45
Number of subjects: 72

Group type: COMPARATOR
Intervention: S90
Number of subjects: 72
Study: 35487299

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg per day for 8 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 21
Study: 34158099

Group type: EXPERIMENTAL
Intervention: Wearable + Symptom Data Algo (Ava bracelet data + Daily Symptom Diary data)
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Symptom Only Algo (Daily Symptom Diary data alone)
Number of subjects: 20000
Study: 70655980

Group type: EXPERIMENTAL
Intervention: Everolimus (EVR) 3-8 ng/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Everolimus (EVR) 6-12 ng/mL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (Mycophenolate sodium 1.44 g/day with standard dose CsA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both EVR groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Everolimus (EVR)
Number of subjects: 0
Study: 33754246

Group type: EXPERIMENTAL
Intervention: Lower intensity physical activity (300 min/week, 40-59% HRR)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Higher intensity physical activity (150 min/week, 60-80% HRR)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No intervention/control
Number of subjects: 45
Study: 34074812

Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 33810609

Group type: EXPERIMENTAL
Intervention: Exercise regimen (12 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Dietary restriction (control group)
Number of subjects: 70
Study: 33275070

Group type: EXPERIMENTAL
Intervention: Low CD4 count (<350 cells/μL)
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Antibiotic use in last 4 weeks
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: CD4 count ≥350 cells/μL
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Overall prevalence of ESBL‐PE carriage
Number of subjects: 595
Study: 32282934

Group type: EXPERIMENTAL
Intervention: Standard information and a reminder letter
Number of subjects: 184

Group type: COMPARATOR
Intervention: Standard information according to clinical routine
Number of subjects: 184
Study: 32631427

Group type: EXPERIMENTAL
Intervention: Eurythmy therapy (ERYT)
Number of subjects: 196

Group type: COMPARATOR
Intervention: CoordiFit (control)
Number of subjects: 196
Study: 35136919

Group type: EXPERIMENTAL
Intervention: Social threat condition (participants rejected by confederates)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Social acceptance condition (participants supported by confederates)
Number of subjects: 83
Study: 33933722

Group type: EXPERIMENTAL
Intervention: n-3 (EPA + DHA)
Number of subjects: 39

Group type: COMPARATOR
Intervention: n-6 (LA)
Number of subjects: 39
Study: 34266520

Group type: EXPERIMENTAL
Intervention: Leg amputation method
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cardiocentesis
Number of subjects: 24
Study: 32622346

Group type: EXPERIMENTAL
Intervention: Intensive BP therapy (<120/80 mm Hg)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Standard BP therapy (<140/90 mm Hg)
Number of subjects: 123
Study: 35226703

Group type: EXPERIMENTAL
Intervention: Compression Garment (CG)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sports Pants (SP)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Compression Garment (CG) and Sports Pants (SP)
Number of subjects: 12
Study: 32715152

Group type: EXPERIMENTAL
Intervention: Unilateral thoracic sympathectomy in dominant side
Number of subjects: 200

Group type: COMPARATOR
Intervention: One-stage bilateral thoracic sympathectomy
Number of subjects: 200
Study: 34981703

Group type: EXPERIMENTAL
Intervention: Diet with 75% of total carbohydrates as whole grains
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diet with 75% of total carbohydrates as refined grains
Number of subjects: 0
Study: 32023922

Group type: EXPERIMENTAL
Intervention: Angelica Gigas Nakai Extract (AGNE) 1 g/day (200 mg/dose) for 12 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 34688549

Group type: EXPERIMENTAL
Intervention: Proton therapy (PT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Photon radiation therapy (IMRT)
Number of subjects: 0
Study: 33302644

Group type: EXPERIMENTAL
Intervention: Fan-zhen Jie-ci (FZJC) acupuncture therapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Routine acupuncture treatment
Number of subjects: 76
Study: 32107266

Group type: EXPERIMENTAL
Intervention: SPIOMET treatment (low-dose combination of spironolactone, pioglitazone, and metformin)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 51

Group type: COMPARATOR
Intervention: Oral contraception-based treatment
Number of subjects: 51
Study: 36114656

Group type: EXPERIMENTAL
Intervention: internet-delivered cognitive behavioral therapy (iCBT)
Number of subjects: 5017

Group type: COMPARATOR
Intervention: general-information (control)
Number of subjects: 5017
Study: 33091857

Group type: EXPERIMENTAL
Intervention: Propolis oral spray (2-4 sprays three times/day for five days, total polyphenol content 15 mg/ml)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Propolis oral spray
Number of subjects: 122
Study: 32442153

Group type: EXPERIMENTAL
Intervention: PLAN intervention (digital and dietetic-delivered program)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Face-to-face dietitian consultations, weight tracker, website information delivery, SMS goal prompting
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: PLAN intervention
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Qualitative analysis of intervention components
Number of subjects: 22
Study: 34750839

Group type: EXPERIMENTAL
Intervention: Rocuronium 12.0 μg·kg‐1 ·min‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Rocuronium 6.0 μg·kg‐1 ·min‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Rocuronium 9.0 μg·kg‐1 ·min‐1
Number of subjects: 120

Group type: COMPARATOR
Intervention: Rocuronium 6.0 μg·kg‐1 ·min‐1 and 9.0 μg·kg‐1 ·min‐1
Number of subjects: 120
Study: 34270094

Group type: EXPERIMENTAL
Intervention: Pfizer vaccine
Number of subjects: 1736

Group type: EXPERIMENTAL
Intervention: AstraZeneca vaccine
Number of subjects: 1736

Group type: EXPERIMENTAL
Intervention: Sinopharm vaccine
Number of subjects: 1736

Group type: EXPERIMENTAL
Intervention: All vaccines
Number of subjects: 1736

Group type: EXPERIMENTAL
Intervention: Unusual side effects
Number of subjects: 1736
Study: 32648393

Group type: EXPERIMENTAL
Intervention: Long-snake moxibustion
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ginger-partitioned moxibustion at ashi point
Number of subjects: 120

Group type: COMPARATOR
Intervention: Waiting for treatment group
Number of subjects: 120
Study: 35866597

Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve strain Bif195
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 33926653

Group type: EXPERIMENTAL
Intervention: High Sodium (HS) diet (300 mEq sodium/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Low Sodium (LS) diet (10 mEq sodium/day)
Number of subjects: 14
Study: 32410601

Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL)
Number of subjects: 405
Study: 35451469

Group type: EXPERIMENTAL
Intervention: 3.2 g of magnesium daily (4 tablets of 0.4 g each twice daily) for 72 hours preoperatively and 1.6 g of magnesium on the day of surgery
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 200
Study: 32572800

Group type: EXPERIMENTAL
Intervention: BUPA + OXY
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: BUPA + ITMs
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: BUPA + OXY + ITMs
Number of subjects: 43
Study: 32651030

Group type: EXPERIMENTAL
Intervention: Integrative approach consisting of 12 sessions of 90 min each, including psychoeducation, mindfulness training, and cognitive and functional enhancement strategies.
Number of subjects: 132

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 132
Study: 36429384

Group type: EXPERIMENTAL
Intervention: MIND Diet
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: MIND Diet plus Forest Bathing (FB)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 72
Study: 34955774

Group type: EXPERIMENTAL
Intervention: Active tDCS (tDCSa)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham tDCS (tDCSs)
Number of subjects: 26
Study: 32636239

Group type: EXPERIMENTAL
Intervention: TMB radiomic biomarker (TMBRB) developed using 3D-densenet and 1020 deep learning features.
Number of subjects: 327

Group type: COMPARATOR
Intervention: TMBRB compared to histological subtype.
Number of subjects: 327

Group type: COMPARATOR
Intervention: TMBRB compared to Radiomic model.
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: TMBRB predicting immunotherapy efficacy.
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: TMBRB combined with Eastern Cooperative Oncology Group performance status.
Number of subjects: 327
Study: 36169994

Group type: EXPERIMENTAL
Intervention: Calm mindfulness app
Number of subjects: 1029
Study: 33481482

Group type: EXPERIMENTAL
Intervention: Simulated sunlight (1.3× standard erythemal dose, three times per week for 4 weeks and then once per week for 8 weeks)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 (1000 IU·d‐1 for 4 weeks and then 400 IU·d‐1 for 8 weeks)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 32924893

Group type: EXPERIMENTAL
Intervention: Performance goals
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Avoidance coping condition
Number of subjects: 121

Group type: COMPARATOR
Intervention: Distraction coping condition
Number of subjects: 121
Study: 33370477

Group type: EXPERIMENTAL
Intervention: third-party bone marrow-derived MSC infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: standard of care alone
Number of subjects: 20
Study: 36445909

Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound at 0.4 W/cm2 and 100% duty cycle
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound at varying intensities and duty cycles
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound at varying intensities
Number of subjects: 28
Study: 32534731

Group type: EXPERIMENTAL
Intervention: PPV-guided fluid management strategy (fluids given whenever PPV was higher than 12%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Liberal fluid strategy (10 mL.kg‐1.h‐1 following institutional standard care protocol)
Number of subjects: 40
Study: 35001863

Group type: EXPERIMENTAL
Intervention: Three-dimensional endoscope
Number of subjects: 70

Group type: COMPARATOR
Intervention: Two-dimensional endoscope
Number of subjects: 70
Study: 33905827

Group type: EXPERIMENTAL
Intervention: Lavandula angustifolia essential oil inhalation for 29 days
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (sunflower oil) inhalation for 29 days
Number of subjects: 35